|
Volumn 331, Issue 6015, 2011, Pages 284-
|
HIV prevention in women: Next steps
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTIRETROVIRUS AGENT;
ANTIVIRUS AGENT;
EMTRICITABINE PLUS TENOFOVIR DISOPROXIL;
PLACEBO;
TENOFOVIR;
ANTIVIRAL THERAPY;
COITUS;
COST EFFECTIVENESS ANALYSIS;
DRUG COST;
DRUG EFFICACY;
DRUG SAFETY;
FEMALE;
FOOD AND DRUG ADMINISTRATION;
GEL;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
INFECTION PREVENTION;
LETTER;
PATIENT COMPLIANCE;
PHASE 3 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
TREATMENT DURATION;
TREATMENT RESPONSE;
UNSPECIFIED SIDE EFFECT;
VIRUS REPLICATION;
VIRUS RESISTANCE;
|
EID: 78751681209
PISSN: 00368075
EISSN: 10959203
Source Type: Journal
DOI: 10.1126/science.331.6015.284-a Document Type: Letter |
Times cited : (14)
|
References (11)
|